Pharmacodynamics of Qingxin Jieyu Granules for treatment of atherosclerosis and its regulatory mechanism for lipid metabolism

doi:10.12122/j.issn.1673-4254.2024.08.10

Abstract

Abstract:

Objective To elucidate the therapeutic mechanism of Qingxin Jieyu Granule (QXJYG) against atherosclerosis (AS) based on network pharmacology. Methods The major targets and pathways of QXJYG against AS were analyzed using network pharmacology. Rat models of AS established by high-fat feeding combined with intraperitoneal vitamin D3 injection were treated daily with normal saline, atorvastatin (13.15 mg/kg), or QXJYG at 0.99, 1.98, and 3.96 g/kg for 8 weeks (n=6). Ultrasound and HE staining were used to assess the function and pathologies of the abdominal aorta. Blood lipids and serum levels of Ang II, ET-1, TXA2, PGI2, and ox-LDL of the rats were detected using an automatic biochemical analyzer or ELISA. The expressions of LOX-1, PPARγ, RXRα, p-P65, VCAM-1 and ICAM-1 in the abdominal aorta were detected with immunohistochemistry. Results The rat models of AS showed obvious abdominal aorta wall thickening, increased pulse wave velocity and pulse index, decreased inner diameter of the abdominal aorta, elevated levels of TC, LDL-C, Ang II, ET-1 and TXA2, and lowered levels of HDL-C and PGI2. QXJYG and atorvastatin treatment of the rat models significantly alleviated histopathological changes of the abdominal aorta, decreased serum levels of TC, LDL-C, Ang II, ET-1 and TXA2, and increased the levels of HDL-C and PGI2. Network pharmacology study suggested the therapeutic effect of QXJYG against AS was mediated by regulating lipid metabolism, PPAR and NF‑κB pathways. Consistently, treatments with QXJYG were found to significantly decrease ox-LDL level and LOX-1, P-P65, VCAM-1 and ICAM-1 protein expressions while increasing PPARγ and RXRα expressions in the aorta of AS rats. Conclusion QXJYG alleviates lipid metabolism disorder and improves histopathological changes of the abdominal aorta of AS rats possibly by lowering ox-LDL level, reducing LOX-1 expression, activating PPARγ and RXRα, and inhibiting P65 phosphorylation to reduce VCAM-1 and ICAM-1 expression in the aorta.

Key words: Qingxin Jieyu Granule, atherosclerosis, network pharmacology, PPARγ/RXRα signaling pathway, NF-κB signaling pathway

Shanyuan ZHANG, Qiaoyan CAI, Jianghan QI, Kaixin YIN, Chenchen HE, Zhuye GAO, Ling ZHANG, Jianfeng CHU. Pharmacodynamics of Qingxin Jieyu Granules for treatment of atherosclerosis and its regulatory mechanism for lipid metabolism[J]. Journal of Southern Medical University, 2024, 44(8): 1518-1528.

Figures/Tables 10

Fig.1 Effects of QXJYG on vessel wall thickness, pulse wave propagation velocity, pulsatility index and vessel diameter in atherosclerotic rats. A, B: Ultrasound images and quantitative comparison of wall thickness of the abdominal aorta. C, D: Sonograms and quantitative comparison of pulse-wave propagation velocity of the abdominal aorta. E, F: Echocardiograms and quantitative analysis of the pulsatility index of the abdominal aorta. G, H: Ultrasound images and quantitative analysis of abdominal aorta vessel diameter. LPT: Positive control (atorvastatin) group; LD: Low-dose QXJYG group; MD: Medium-dose QXJYG group; HD: High-dose QXJYG group. *P<0.05 vs Control group; #P<0.05 vs Model group; △P<0.05 vs LD group; &P<0.05 vs MD group.

Fig.2 Effects of QXJYG on vascular pathology of the abdominal aorta in rats with atherosclerosis (HE staining, Scale bar=50 µm).①Intimal thickening of the blood vessels; ②Proliferation of smooth muscle cells with disordered arrangement.

Fig.3 Effects of QXJYG on serum levels of TC, LDL-C, TG and HDL-C in rats with atherosclerosis. A: Serum levels of TC and LDL-C. B: Serum levels of TG and HDL-C. *P<0.05 vs Control group; #P<0.05 vs Model group; △P<0.05 vs LD group.

Fig.4 Effects of QXJYG on serum levels of Ang II (A), ET-1 (B), TXA2 (C) and PGI2 (D) in rats with atherosclerosis. *P<0.05 vs Control group; #P<0.05 vs Model group; △P<0.05 vs LD group; &P<0.05 vs MD group.

Fig.5 Analysis of targets of QXJYG and AS. A: Quantity diagram of each drug compound of QXJYG. B: Number of drug targets of QXJYG. C: Venn diagram of QXJYG and AS targets. D: PPI plot of potential protein interaction of QXJYG against AS.

Tab.1 Cross targets of QXJYG with anti-AS values higher than the average value

Key target	Degree	Betweenness centrality	Closeness centrality
IL-6	21	0.14771628	0.83870968
IL-1B	19	0.0880959	0.78787879
PPARG	19	0.20820912	0.78787879
VCAM1	16	0.03766667	0.7027027
IL-10	14	0.02131169	0.66666667
SERPINE1	14	0.01293806	0.65
ESR1	14	0.04946542	0.65
SPP1	14	0.01452414	0.65
CRP	13	0.00772194	0.63414634
SIRT1	13	0.04028405	0.65
NOS3	13	0.01529604	0.63414634
MMP3	11	0.00423576	0.57777778
SELE	10	0.00117216	0.59090909

Fig.6 KEGG pathway enrichment analysis and GO functional analysis of QXJYG against AS.A: KEGG pathway enrichment analysis of QXJYG against AS. B: Biological processes analysis of QXJYG against AS. C: Cell components analysis of QXJYG against AS. D: Molecular function analysis of QXJYG against AS.

Fig.7 Effect of QXJYG on serum ox-LDL in atherosclerotic rats. *P<0.05 vs Control group; #P<0.05 vs Model group; △P<0.05 vs LD group.

Fig.8 Effect of QXJYG on the expression of LOX-1, PPARγ, RXRα and p-P65 in the abdominal aorta of atherosclerotic rats (DAB staining, original magnification: ×400). A, B: LOX-1 expression and positivity rate in the abdominal aorta. C, D: PPARγ expression and positivity rate in the abdominal aorta. E, F: Expression of RXRα and positivity rate positive rate. G, H: Expression of p-P65 and positivity rate. *P<0.05 vs Control group; #P<0.05 vs Model group; △P<0.05 vs LD group; &P<0.05 vs MD group.

Fig.9 Effect of QXJYG on the expression of VCAM-1 and ICAM-1 in abdominal aorta of atherosclerotic rats (DAB staining, ×400). A, B: VCAM-1 expression and positivity rate in the abdominal aorta. C, D: ICAM-1 expression and positivity rate in the abdominal aorta. *P<0.05 vs Control group; #P<0.05 vs Model group; △P<0.05 vs LD group.

References 32

1	马丽媛, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023, 9(32): 3975-94.
2	赵冬. 新中国成立70年来我国人群血脂流行病学研究回顾与进展[J]. 中国医药, 2019, 14(10): 1441-4.
3	王吉耀. 内科学[M]. 2版. 北京: 人民卫生出版社, 2010: 267-74.
4	Ibanez B, Fernández-Ortiz A, Fernández-Friera L, et al. Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7/8[J]. J Am Coll Cardiol, 2021, 78(2): 156-79.
5	Yin LQ, Wang LH, Shi ZH, et al. The role of peroxisome proliferator-activated receptor gamma and atherosclerosis: post-translational modification and selective modulators[J]. Front Physiol, 2022, 13: 826811.
6	Gao LN, Zhou X, Lu YR, et al. Dan-Lou prescription inhibits foam cell formation induced by ox-LDL via the TLR4/NF-κB and PPARγ signaling pathways[J]. Front Physiol, 2018, 9: 590.
7	李银花, 贾张蓉, 江龙, 等. 血脂康对冠心病合并高脂血症患者疗效的Meta分析[J]. 中国循证心血管医学杂志, 2014, 6(1): 25-30.
8	Zhang Z, Gao J, Wang J, et al. Mechanism of Zhishi Xiebai Guizhi decoction to treat atherosclerosis: Insights into experiments, network pharmacology and molecular docking. J Ethnopharmacol, 2024, 333: 118466.
9	Zhi W, Liu Y, Wang X, et al. Recent advances of traditional Chinese medicine for the prevention and treatment of atherosclerosis[J]. J Ethnopharmacol, 2023, 301: 115749.
10	李圣耀, 杨琳, 高铸烨, 等. 清心解瘀方组方中药入血成分的网络药理学分析[J]. 中国实验方剂学杂志, 2018, 24(5): 198-202.
11	高翔. 清心解瘀方干预炎症反应增强的稳定性冠心病患者临床研究[D]. 北京: 中国中医科学院, 2017.
12	李金根. 清心解瘀方对稳定性冠心病临床终点事件影响的随机双盲对照研究[D]. 北京: 北京中医药大学, 2018.
13	鞠建庆. 清心解瘀方调控巨噬细胞焦亡稳定动脉粥样硬化易损斑块的机制研究[D]. 北京: 北京中医药大学, 2019.
14	Zhang J, Wang XY, Guan BY, et al. Qing-Xin-Jie-Yu Granule inhibits ferroptosis and stabilizes atherosclerotic plaques by regulating the GPX4/xCT signaling pathway[J]. J Ethnopharmacol, 2023, 301: 115852.
15	Wang AL, Guan BY, Shao C, et al. Qing-Xin-Jie-Yu Granule alleviates atherosclerosis by reshaping gut microbiota and metabolic homeostasis of ApoE^-/- mice[J]. Phytomedicine, 2022, 103: 154220.
16	Zhu ZS, Li JY, Zhang XR. Astragaloside IV protects against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury by reducing oxidative stress and inflammation[J]. Med Sci Monit, 2019, 25: 2132-40.
17	Zhang YF, Feng XT, Du M, et al. Salvianolic acid B attenuates the inflammatory response in atherosclerosis by regulating MAPKs/NF-κB signaling pathways in LDLR^-/- mice and RAW_264.7 cells[J]. Int J Immunopathol Pharmacol, 2022, 36: 3946320221079468.
18	李洪涛, 邓宇, 王添乐, 等. 丹参新醌乙减轻ox-LDL诱导的内皮细胞损伤: 基于抑制NF-κB/NLRP3信号通路介导的细胞焦亡[J]. 南方医科大学学报, 2023, 9(8): 1425-31.
19	Li L, Chen HW, Shen AL, et al. Ligustrazine inhibits platelet activation via suppression of the Akt pathway[J]. Int J Mol Med, 2019, 43(1): 575-82.
20	Zhuang Z, Wang ZH, Huang YY, et al. Protective effect and possible mechanisms of ligustrazine isolated from Ligusticum wallichii on nephropathy in rats with diabetes: a preclinical systematic review and meta-analysis[J]. J Ethnopharmacol, 2020, 252: 112568.
21	张伟, 张娟娟, 郭庆丰, 等. 广藿香醇药理作用研究进展[J]. 中国实验方剂学杂志, 2020, 26(3): 213-21.
22	Zhao JV, Yeung WF, Chan YH, et al. Effect of berberine on cardiovascular disease risk factors: a mechanistic randomized controlled trial[J]. Nutrients, 2021, 13(8): 2550.
23	Song T, Chen WD. Berberine inhibited carotid atherosclerosis through PI3K/AKTmTOR signaling pathway[J]. Bioengineered, 2021, 12(1): 8135-46.
24	陈超, 张瑞芬, 张海荣. PPAR-γ与动脉粥样硬化及其危险因素的相关研究进展[J]. 中国循证心血管医学杂志, 2021, 13(9): 1146-7.
25	樊碧娆, 姚伟娟. 氧化型低密度脂蛋白受体在动脉粥样硬化发病机制中的作用[J]. 中国病理生理杂志, 2020, 36(10): 1897-901.
26	Yang XF, Shang DJ. The role of peroxisome proliferator-activated receptor γ in lipid metabolism and inflammation in atherosclerosis[J]. Cell Biol Int, 2023, 47(9): 1469-87.
27	汤银娟, 王建钧, 关莹露, 等. 阿托伐他汀对高胆固醇血症大鼠侧支血管中LOX-1和eNOS表达的影响[J]. 南方医科大学学报, 2019, 39(11): 1265-72.
28	Tang H, Zeng QF, Tang T, et al. Kaempferide improves glycolipid metabolism disorder by activating PPARγ in high-fat-diet-fed mice[J]. Life Sci, 2021, 270: 119133.
29	Zhang BH, Hao ZW, Zhou WL, et al. Formononetin protects against ox-LDL-induced endothelial dysfunction by activating PPAR‑γ signaling based on network pharmacology and experimental validation[J]. Bioengineered, 2021, 12(1): 4887-98.
30	Guo H, Cui BD, Gong M, et al. An ethanolic extract of Arctium lappa L. leaves ameliorates experimental atherosclerosis by modulating lipid metabolism and inflammatory responses through PI3K/Akt and NF‑κB singnaling pathways[J]. J Ethnopharmacol, 2024, 325: 117768.
31	Ebrahimi F, Ghazimoradi MM, Fatima G, et al. Citrus flavonoids and adhesion molecules: potential role in the management of atherosclerosis[J]. Heliyon, 2023, 9(11): e21849.
32	Adam CA, Șalaru DL, Prisacariu C, et al. Novel biomarkers of atherosclerotic vascular disease-latest insights in the research field[J]. Int J Mol Sci, 2022, 23(9): 4998.

[1]	Xingmei CHEN, Qinwen LIU, Yi LI, Xiaoyu ZHONG, Qiling FAN, Ke MA, Liuting LUO, Daogang GUAN, Zhibo ZHU. Analysis of core functional components in Yinchenhao Decoction and their pathways for treating liver fibrosis [J]. Journal of Southern Medical University, 2024, 44(8): 1508-1517.
[2]	Jinjin WANG, Wenfei CUI, Xuewei DOU, Binglei YIN, Yuqi NIU, Ling NIU, Guoli YAN. Euonymus alatus delays progression of diabetic kidney disease in mice by regulating EGFR tyrosine kinase inhibitor resistance signaling pathway [J]. Journal of Southern Medical University, 2024, 44(7): 1243-1255.
[3]	Linyue WANG, Wenyue QI, Jihua GAO, Maosheng TIAN, Jiancheng XU. Tongyangxiao Lotion promotes postoperative wound healing in a rat model of anal fistula by downregulating inflammatory factors and suppressing inflammation [J]. Journal of Southern Medical University, 2024, 44(7): 1256-1265.
[4]	Wenxiang ZHANG, Huixian GU, Pengde CHEN, Siyu WU, Hongyan MA, Lan YAO. Compound Yuye Decoction protects diabetic rats against cardiomyopathy by inhibiting myocardial apoptosis and inflammation via regulating the PI3K/Akt signaling pathway [J]. Journal of Southern Medical University, 2024, 44(7): 1306-1314.
[5]	Yan HUANG, Lulu QIN, Shaoxing GUAN, Yanping GUANG, Yuru WEI, Ailing CAO, Dongmei LI, Guining WEI, Qibiao SU. Therapeutic mechanism of aqueous extract of Semiliquidambar cathayensis Chang root for pancreatic cancer: the active components, therapeutic targets and pathways [J]. Journal of Southern Medical University, 2024, 44(7): 1336-1344.
[6]	Zhijun REN, Jianxin DIAO, Yiting WANG. Xionggui Decoction alleviates heart failure in mice with myocardial infarction by inhibiting oxidative stress-induced cardiomyocyte apoptosis [J]. Journal of Southern Medical University, 2024, 44(7): 1416-1424.
[7]	Ruibo LI, Ge GAO, Xi XIE, Haibin LUO. Oral submucosal fibrosis induced by active components in areca nut: a network pharmacology-based analysis and validation of the mechanism [J]. Journal of Southern Medical University, 2024, 44(5): 930-940.
[8]	LI Yunfei, YANG Jingyi, ZHANG Ying, ZHANG Caixia, WEI Yuxiang, WANG Yiying, WU Ning, SUN Jianfei, WU Zunqiu. The Miao medicine Sidaxue alleviates rheumatoid arthritis in rats possibly by downregulating matrix metalloproteinases [J]. Journal of Southern Medical University, 2024, 44(4): 739-747.
[9]	CHEN Junjie, HUANG Chuanbing, LI Ming. Jianpi Zishen granule inhibits podocyte autophagy in systemic lupus erythematosus: a network pharmacology and clinical study [J]. Journal of Southern Medical University, 2024, 44(3): 465-473.
[10]	CUI Yixin, WANG Decai, XIE Dongqing, WANG Haiming, XU Ruixin, TANG Xiaoran, ZHANG Yin. Efficacy of navel application of Jianpiwenyang Gel for chronic diarrhea of spleen and stomach weakness type: a randomized controlled trial and analysis of the mechanism [J]. Journal of Southern Medical University, 2024, 44(2): 217-225.
[11]	ZHANG Qian, ZHANG Meikui, LIU Yinglu, WANG Yan, LV Feifei, WANG Yuguo. Exploring the therapeutic mechanism of Liuwei Suanzao decoction for perimenopausal insomnia based on network pharmacology and animal experiments [J]. Journal of Southern Medical University, 2023, 43(9): 1536-1547.
[12]	ZHANG Xuefang, CHEN Yanhua, LI Zongheng, SHANG Jing, YUAN Zeting, DENG Wanli, LUO Ying, HAN Na, YIN Peihao, YIN Jun. Analysis of therapeutic mechanism of Liushen Wan against colitis-associated colorectal cancer based on network pharmacology and validation in mice [J]. Journal of Southern Medical University, 2023, 43(7): 1051-1062.
[13]	LIU Fang, ZHANG Yuanfang, LIU Peng, LIU Jiamin, LIU Siyu, WANG Junjie. UPLC-Q-TOF-MS/MS combined with network pharmacology for exploring anti-inflammatory mechanism of Eurycoma longifolia [J]. Journal of Southern Medical University, 2023, 43(6): 879-888.
[14]	LUO Guanfeng, LIU Huaxi, XIE Bei, DENG Yijian, XIE Penghui, ZHAO Xiaoshan, SUN Xiaomin. Therapeutic mechanism of Shenbing Decoction III for renal fibrosis in chronic kidney disease: a study with network pharmacology, molecular docking and validation in rats [J]. Journal of Southern Medical University, 2023, 43(6): 924-934.
[15]	SUN Yang, XU Yibo, XIAO Linyu, ZHU Guoqing, LI Jing, SONG Xue, XU Lei, HU Jianguo. Acetylcorynoline inhibits microglia activation by regulating EGFR/MAPK signaling to promote functional recovery of injured mouse spinal cord [J]. Journal of Southern Medical University, 2023, 43(6): 915-923.